Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YEXT 6/16 $10C in @.46 just hit $4
How high could it go in the next 9 days?
I guess the right move would b to sell the option and join the option millionaires
How high do you think the 6/16 $YEXT $10 CALL can go before expiration? I'm not experienced enough to know when to sell my last call option that I'm in @ .46
Unfortunately I sold my other one yesterday @ .50 after it was down to .10 to put the $50 cash back in my account not knowing/realizing earnings were this morning
$SOFI & $YEXT calls are like frosted flakes this morning...
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13 2023 - 08:45PM
GlobeNewswire Inc
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those responses.
Alvotech’s second BLA for AVT02, which contains data to support approval as a biosimilar and additional information supporting potential interchangeability designation – remains under review by the FDA, with a Biosimilar User Fee Amendment (BsUFA) goal date of June 28, 2023. Satisfactory outcome of the facility reinspection remains the key requirement for approval.
“We look forward to working with the FDA to resolve any outstanding issues identified in the reinspection,” said Robert Wessman, Chairman and CEO of Alvotech. “We are committed to manufacturing AVT02 for patients in the United States, especially a potentially differentiated Humira biosimilar that provides a high-concentration formulation and is interchangeable.”
About AVT02
AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in the 27 EU member countries, Norway, Lichtenstein, Iceland, the UK, Switzerland, Canada, Australia and Saudi Arabia. It is currently marketed in sixteen countries in Europe and in Canada. Dossiers are under review in multiple countries, including in the United States.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Just to be clear the company name is ALVOTECH not alvoNtech which was an error while creating the board. I will fix it asap. The stock symbol is ALVO
Alvotech
https://www.alvotech.com/
We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.
It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.
Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.
We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
could this be shorts covering due to GERN raising cash?
I have no clue how high it will go but you should cash out your initial investment at minimum. Then the "greedy" feeling will be reduced and you should consider finding another investment that your interested in. If you don't need the money right now you could put your initial investment money that will be cashed out of EXPI back to work in your new investment idea. If you currently could use the cash from the sale in your daily life I recommend using it for that if it will make your life easier, less stressful and/or more enjoyable. If that is the case I would recommend putting the initial investment money that you cash out back into your daily life funds. If you have another investment idea and you chose to pocket the initial investment funds don't hesitate to sell more EXPI shares to also fund your new investment idea. At that point you've enriched your daily life... have a new investment... and you still hold free EXPI shares that hopefully continue to rise. I am not a professional investment manager and I've made many investment mistakes so in the end do whatever you can live with, without setting yourself up for future regrets. I'm just trying to be a voice of balanced reason without knowing your situation. Good luck and congrats!
I hope everyone here is reaping the rewards of getting in low & holding onto this rocket of a stock. Congrats.
Wish I would've taken my own advice under $10... Now I'm chasing.
I was just a little early with the ATH's coming call... Look at this now. Parabolic.
EDGERRIN JAMES TRICKS OUT CAR FOR HALL OF FAME...
https://www.tmz.com/2020/09/25/edgerrin-james-hall-of-fame-car-colts-chevy-caprice/
I'm thinking it was spun off so it could be acquired...
Cerence Inc. (NASDAQ: CRNC), AI for a world in motion. Developing game-changing innovations for the automotive cockpit of the future.
My cousin works for Nuance and told me about this spinoff @ $21.96
We need this symbol updated to CRNC
From VIVO Cannabis First Quarter 2020 Results:
Subsequent to quarter-end, VIVO signed an exclusive agreement with Vertosa, an infusion technology company based in Oakland, California. The agreement provides rights to their advanced technology for Canada. Vertosa's patent pending emulsion systems allow for the creation of shelf-stable cannabis infused beverages, with high bioavailability, excellent clarity, and great taste. VIVO plans to install new equipment in its Napanee facility over the next few months to produce emulsification products for use in future cannabis beverages for VIVO and third-party product developers throughout Canada.
I found the bold info at the end very interesting. These were posts from the Canopy board. VIVO is selling top notch product.
Bazwar6 Wednesday, 05/06/20 01:09:24 PM
Re: None 0
Post # 119173 of 119196
Placed my Ontario cannabis order 53 hours ago BakerStreet and ginger
Still have not received an email saying it has been shipped. Must be smoking busy
GreenKnight Member Level Wednesday, 05/06/20 02:14:20 PM
Re: Bazwar6 post# 119173 0
Post # 119175 of 119196
Ordered on Monday night and got confirmation today. System is slow I think. Also now I see rosin on there .... hash rosin at $70/g is fair enough.... maybe $50-$70 — but it’s sold OUT because Live Rosin from Cannafarms is fetching $120/g???? Totally crazy.
I found the bold info at the end very interesting. These were posts from the Canopy board. VIVO is selling top notch product.
Bazwar6 Wednesday, 05/06/20 01:09:24 PM
Re: None 0
Post # 119173 of 119196
Placed my Ontario cannabis order 53 hours ago BakerStreet and ginger
Still have not received an email saying it has been shipped. Must be smoking busy
GreenKnight Member Level Wednesday, 05/06/20 02:14:20 PM
Re: Bazwar6 post# 119173 0
Post # 119175 of 119196
Ordered on Monday night and got confirmation today. System is slow I think. Also now I see rosin on there .... hash rosin at $70/g is fair enough.... maybe $50-$70 — but it’s sold OUT because Live Rosin from Cannafarms is fetching $120/g???? Totally crazy.
News Release Issued: Mar 27, 2020 (3:25pm EDT)
VIVO Cannabis to Host Conference Call for Fourth Quarter 2019 Results
NAPANEE, ON, March 27, 2020 /CNW/ - VIVO Cannabis Inc. (TSX: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company") today announced that senior management will host a conference call on Tuesday, March 31, 2020 at 10 a.m. ET to discuss the Company's fourth quarter 2019 results.
VIVO Cannabis Inc. (CNW Group/VIVO Cannabis Inc.)
Conference call details:
DATE:
Tuesday, March 31, 2020
TIME:
10:00 a.m. ET
DIAL-IN NUMBER:
647-427-7450 or 1-888-231-8191
CONFERENCE ID:
7125668
TAPED REPLAY:
416-849-0833 or 1-855-859-2056
Reference number 7125668
Available until Friday, April 6, 2020
LIVE WEBCAST:
http://bit.ly/2VIARP0
Webcast will be archived for 90 days
VIVO will release its fourth quarter 2019 results on Monday, March 30, 2020, after the close of markets.
News Release Issued: Mar 20, 2020 (9:28am EDT)
VIVO Cannabis™ provides Update Regarding COVID-19
NAPANEE, ON, March 20, 2020 /CNW/ - VIVO Cannabis Inc. (TSX: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company") today announced the Company, its production facilities and medical clinics are continuing to respond to COVID-19 with changes to internal business practices consistent with the guidelines of public health authorities. As VIVO continues to monitor the COVID-19 pandemic, the health and safety of its customers and employees remains the Company's top priority.
VIVO Cannabis Inc. (CNW Group/VIVO Cannabis Inc.)
"As we navigate this ever-evolving situation, we have implemented several measures to protect our employees, while allowing us to continue to operate our business," said Barry Fishman, CEO of VIVO. "We are continuing to monitor the latest developments and the guidance from government bodies and public health authorities. Our commitment to strong corporate governance, sound business judgement and proactive actions are more important now than ever."
For the past several weeks, VIVO has been actively monitoring COVID-19 developments and taking the necessary precautions for its business. VIVO has encouraged all employees to suspend travel, work from home when possible, and enhanced the use of personal protective equipment to reduce the risk of COVID-19 exposure and spread. The Company has also deployed more rigorous cleaning and sanitization efforts across all of its sites and continues to assess its facilities and clinics as the situation continues to evolve. At present, VIVO's production facilities are continuing operations and have no confirmed cases of COVID-19.
According to a survey of recreational cannabis users conducted by Deloitte, 59% of respondents consume at home alone. Spurred by an environment of uncertainty and anxiety, recent trends indicate that many consumers and patients are stocking-up on product in response to fears of shortages and lack of access. The Company has already seen a short-term increase in sales on its medical platform. Although this is anticipated to be temporary, it demonstrates VIVO's dedication to satisfying consumer and patient needs.
VIVO is doing everything possible for its valued customers, including ensuring that our medical patients will continue to have access to the cannabis products on which they depend. The Company has temporarily suspended all in-clinic visits at its Harvest Medicine centres in Calgary, Edmonton, Moncton and Dartmouth and has expanded its telemedicine platform of phone and video consultations, including its HMED Connect App. The Company's dedicated team of clinicians and educators continue to be available and provide support.
Medical patients can continue to access their treatments across a range of high quality cannabis products from Canna Farms online. VIVO is committed to prioritizing consistent supply of medical cannabis for patients in need during these unprecedented times. If patients have concerns, they should contact the Canna Farms Patient Services teams at info@cannafarms.ca or Harvest Medicine at info@hmed.ca.
I'm watching it creep up with you... I went with the Feb 21st $26 strike and I'm in at .9133
So far they are looking good.
RDFN looking to break out... Earnings coming up on the 12th.
Wonder why FanDuel owner (PDYPY) doesn't get any attention? I personally play more on FD but I like DK too.
JB... I'm still really just learning on options. I played a bit a couple years ago and did well on a few. I was lucky to be holding Mobileye calls when intel bought them out and that was a homerun. But it is tough for me to look at the list and know which to target. When you get a chance can you explain to me which RDFN calls you are targeting and why or how you make the choice? They report earnings on 2/13/20 so I am looking for that to be the upside catalyst. Any help is greatly appreciated. Thanks - LB
Happy New Year to you too! Thanks for the quick response and thoughts. I will be keeping this one on the radar with you... Hopefully you have another potential runner. I had a horrendous 2019 "mentally" stuck in cannabis stocks and got a big account trimming while watching the market get high without me. I feel like a dope but it taught me multiple costly lessons in all of my family members accounts. Young"ish" self-taught and learning as I go I consider it tuition. I'm back and taking action ready to grind out trades and get these accounts back to ATH's. I realize that I am a trader not an investor. I love reading the Option Millionaires thoughts and value your opinions. Carpe Diem! and cheers to a fruitful 2020!
Hey JB... A friend of mine who is a smart Harvard guy told me about Redfin before it ipo'd. He lives in Seattle. I've traded it a few times and I've been watching it all along and I just saw your RDFN post. Any thoughts or pps expectations for 2020? I value your opinion JB... Thanks.
VIVO Cannabis™ Reports Third Quarter 2019 Results
Net revenue was $6.3 million in the quarter, a 19% increase, quarter-over-quarter, and 175% increase over Q3 2018, and $16.6 million year-to-date, a 328% increase over the same period last year.
Adjusted EBITDA(1) was ($2.1) million in Q3 2019 compared to ($1.2) million in Q2 2019, primarily attributable to one-time expenses, including the ramp-up of new licenced capacity.
Healthy balance sheet with $50.1 million in cash and cash equivalents and $6.1 million in strategic investments.
Maintained leadership pricing of $7.15 per gram of dry flower in Q3 2019 (compared with $6.96 in Q2 2019), with VIVO brands earning top position in the ultra-premium category in several Canadian provinces.
Received conditional approval to graduate from the TSX Venture Exchange (the "TSXV") and list common shares on the Toronto Stock Exchange (the "TSX").
Completed first harvest at the new 86,000 square foot Kimmetts airhouse facility in Napanee, Ontario, following the issuance of a standard cultivation licence by Health Canada in August 2019.
Received a licence amendment to begin selling cannabis edibles, concentrates and topicals, with sales of premium cannabis chocolates, bubble hash, rosin, shatter, wax, vape pens and cartridges expected to commence in Ontario and other Canadian markets later this year or early in 2020.
Announced a partnership with Linneo Health, an EU-GMP certified cultivator based in Spain, and received a narcotics licence in Germany that allows for the commercialization of narcotic pharmaceutical products (which includes medical cannabis) in Germany.
Construction of Canna Farms Phase 5 is on track for completion in early Q1 2020, which will add incremental production capacity.
VIVO Cannabis to Host Third Quarter 2019 Financial Results Conference Call
NAPANEE, ON, Nov. 1, 2019 /CNW/ - VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company") today announced that senior management will host a conference call to discuss the Company's third quarter 2019 results. The Company will release its results for the third quarter on Thursday, November 14, 2019, after the close of markets.
Conference call details:
DATE:
Friday, November 15, 2019
TIME:
10:00 am ET
DIAL-IN NUMBER:
647-427-7450 or 1-888-231-8191
CONFERENCE ID:
8630429
TAPED REPLAY:
416-849-0833 or 1-855-859-2056
Reference number 8630429
Available until Friday, November 22, 2019 at midnight
LIVE WEBCAST:
https://bit.ly/31k4aGU
Webcast will be archived for 90 days
BioTime is now Lineage Cell Therapeutics, Inc. LCTX
I have owned shares in and have been following GERN for years as well and I would hate to not own any at this point in time.
Looks like the selling has slowed... If the constant supply of shares to sell dries up the pps should start to trend higher from here. The bid/ask should rise until they find a pps where people are willing to sell shares right? Well that would make sense in a fair balanced equal market... Either way I just topped off my position and I'm waiting for earnings.
If I worked for VIVO and believed in the company I would talk to my coworkers about buying shares relentlessly as a group to make a statement to the public as well as current investors.
LIMBO... I mean VIVO Cannabis Inc.
How low can this stock go?
I like what the company is doing but the stock is brutal to own...
That makes sense to me... I had a feeling somebody has had plenty of shares to dump lately. Brutal and relentless selling... Sucks until they back off because retail investors cant chew through the amount of shares available to dump from Ken & Canna.
Thanks jb... I'll let you know how I do.
So I checked on GPRO's earnings and it looks like I should be in a position to make some profit. Of course I'll be busy tomorrow morning but I'll be checking on it asap. I bought 4 x MAY17 $7 CALLS(@ .30 avg) & 4 x JUNE21 $7 CALLS(@ .50 avg). The pps is $7,27 after hours. My issue is that I suck at selling my profitable options so far. I've sold way to early as well as let profits decay away trying to "let some run" lol. Are there any "rules" or indicators that you normally use to maximize your profits that you are willing to share? If it is just a gut feeling you get with experience... I can appreciate hearing that as well. Thanks in advance.
Any thoughts on GPRO into earnings tomorrow after the close? I've noticed a lot of positive reviews on the new Hero7 black since its release. Go Pro has become the standard go to brand for YouTubers Vloggers and people/families documenting vacations road trips or any film worthy events. I grabbed some May 17th and June 21st $7 calls.
WOW... This stock is brutal lately. So disconnected from fundamentals. Someones got plenty to sell and they have been taking my lunch money every step of the way down since we were trading @ $2.48. I feel like I'm on an episode of Gold Rush... We just gotta get to the bottom of the glory hole! No guts No Glory! Everything seems to be going well except our pps is telling us different...
Example of a Confidential Treatment Order
For example, a company may apply for a confidential treatment order by completing a confidential treatment request to keep information regarding a pricing arrangement made with a potential acquisition target secret. This request could be made on the basis that the company's competitors may use this information to go after the target with a more competitive price. Other common items kept confidential include milestone payments and other technical specifications.
I would love to see GERN get acquired at a nice premium but wouldn't the company that was acquiring GERN file the CTO?